Illumina Short Sellers Retreat Before Q3 Results

Illumina reports Q3 results after the close today, a print that arrives as short sellers have made a clear, deliberate retreat from the stock over the past six weeks.

Short interest has fallen nearly 29% over the past month, dropping to 4.9% of the free float from roughly 7% in late September. The weekly decline alone is 2.6 standard deviations below Illumina's own historical pace of change, a move far outside the normal range of weekly fluctuations. Borrow conditions tell the same story: the lending pool is loose, with availability at 766%, meaning roughly seven shares are available to borrow for every one already lent out. That compares with a 52-week low of 313%, and cost to borrow has drifted down to 0.43%. There is no meaningful squeeze pressure and no sign of forced covering. Shorts are leaving because they want to, not because they have to.

The stock has responded. At $290.06, Illumina is up 7.7% over the past week, though that trails the median gain of 11.3% among its closest peers. Tempus AI added 13% on the week, Maravai LifeSciences rose 12%, and Ginkgo Bioworks surged 33%, so the sector rotation has been broad. The options market is not showing unusual anxiety: the put/call ratio at 0.66 sits slightly below its 20-day average of 0.69, well off the 52-week high of 0.76 hit just two weeks ago. If anything, the options positioning is mildly more constructive than usual going into the number.

Where the debate sits is squarely on durability. The bull case centres on Illumina's clinical sequencing franchise, which has been growing at 17% to 20%, driven by oncology volume, stronger MRD testing adoption and consumables that carry gross margins above 70%. The bear case questions whether that pace can hold: per-sample unit economics are compressing as customers push back on pricing, academic research demand remains soft, and China, once roughly 10% of revenue, has shrunk to about 5% with Illumina still on the unreliable entities list. Analysts have broadly raised targets ahead of the print, with Canaccord lifting to $300, Leerink to $300 and RBC to $310, yet the consensus remains a hold at a mean target of $249, well below the current price. Barclays kept its underweight with a $200 target. The gap between where the optimists are and where the stock actually trades is the central tension in the setup.

One institutional data point worth noting: Director Keith Meister sold more than $26 million worth of shares in early September at prices around $218, a level the stock has since cleared by more than 30%. No comparable open-market buying has followed. FMR LLC added more than 11.6 million shares in the most recent period, now holding over 10% of the company, and BlackRock updated its filing in late October at 8.9%. Illumina was added to the S&P 500 in September, triggering an estimated $6.6 billion of index-tracker buying. ORTEX puts the chance of a further addition to the Nasdaq-100 at the December review at 38%, which would require the stock to close above $347.81, roughly 20% above today's level.

The print will test whether the clinical sequencing acceleration that has driven a 115% year-to-date gain is genuine and repeatable, or whether the magnitude of the move has simply run ahead of what the underlying numbers can support.